Angiotensin 1/2 (2-7): Peptide Fragment for RAS Research

Executive Summary: Angiotensin 1/2 (2-7) is a synthetic peptide fragment derived from angiotensin I and II, encompassing amino acids 2–7 (ARG-VAL-TYR-ILE-HIS-PRO). It is a critical vasoconstrictor peptide in the renin-angiotensin system (RAS), regulating blood pressure and stimulating aldosterone release (APExBIO product information). Recent evidence shows that N-terminal deletions, including angiotensin (2-7), can enhance SARS-CoV-2 spike protein binding to the AXL receptor, with implications for viral pathogenesis (Oliveira et al., 2025). The peptide exhibits high purity (99.80%) and solubility across common laboratory solvents. APExBIO supplies Angiotensin 1/2 (2-7) (SKU A1050) as a research-only reagent, not for clinical or diagnostic use.

Biological Rationale

The renin-angiotensin system (RAS) maintains cardiovascular and renal homeostasis. Angiotensinogen is cleaved by renin to form angiotensin I, which is then processed by angiotensin-converting enzyme (ACE) into angiotensin II. Cleavage of angiotensin II yields further peptide fragments, such as angiotensin 1/2 (2-7), which retain biological activity (Oliveira et al., 2025). Angiotensin 1/2 (2-7) is composed of six amino acids (ARG-VAL-TYR-ILE-HIS-PRO) and acts as a vasoconstrictor, influencing vascular tone and sodium retention. This positions the peptide as a critical tool for blood pressure regulation research and studies into aldosterone release stimulation. Compared to longer peptides such as angiotensin I (1–10), angiotensin 1/2 (2-7) offers unique mechanistic insights due to its fragment-specific activities.

For an expanded review of its multifaceted roles in blood pressure regulation and viral pathogenesis, see this analysis, which this article extends by providing more granular mechanistic and structural detail.

Mechanism of Action of Angiotensin 1/2 (2-7)

Angiotensin 1/2 (2-7) is generated by enzymatic cleavage of angiotensin I or II within the RAS. As a vasoconstrictor peptide, it binds to angiotensin II receptors, initiating contraction of vascular smooth muscle and promoting aldosterone secretion from the adrenal cortex (APExBIO). Aldosterone stimulates sodium retention in the distal nephron, contributing to blood pressure elevation. In recent studies, N-terminally truncated angiotensin peptides, including angiotensin (2-7), have been shown to enhance binding of the SARS-CoV-2 spike protein to the AXL receptor, a mechanism not observed with full-length angiotensin I. This effect is likely mediated by increased interaction surface or allosteric modulation of the receptor (Oliveira et al., 2025).

For additional mechanistic insights into the peptide's advanced roles in the RAS, see this detailed review, which is complemented by the new cross-domain implications discussed here.

Evidence & Benchmarks

• Enzymatic processing of angiotensinogen via renin and ACE produces a cascade of peptides, including angiotensin 1/2 (2-7), with distinct receptor-binding profiles (Oliveira et al., 2025).
• Angiotensin 1/2 (2-7) displays potent vasoconstrictor effects and stimulates aldosterone release, impacting sodium homeostasis and blood pressure (APExBIO).
• N-terminal deletions of angiotensin II, such as angiotensin (2-7), increase SARS-CoV-2 spike protein binding to the AXL receptor by up to 2.7-fold compared to full-length peptides (Oliveira et al., 2025).
• The peptide is supplied as a solid compound with a molecular weight of 783.92 g/mol and a chemical formula of C37H57N11O8 (APExBIO).
• High solubility is reported in water (≥46.6 mg/mL), DMSO (≥78.4 mg/mL), and ethanol (≥2.78 mg/mL), enabling diverse assay formats (APExBIO).
• Shorter angiotensin peptide fragments (including 2-7) potentiate spike–AXL binding more than C-terminal deletions, suggesting N-terminal residues are key to this activity (related review).

Applications, Limits & Misconceptions

Angiotensin 1/2 (2-7) is a tool in blood pressure regulation research, RAS pathway studies, and viral entry investigations. Its high purity and solubility allow for precise dosing in cell-based or biochemical assays. The peptide is not intended for diagnostic or therapeutic use. While it reliably induces vasoconstriction and stimulates aldosterone in vitro, its in vivo pharmacodynamics may differ due to rapid proteolytic degradation.

This article updates prior reviews by integrating up-to-date SARS-CoV-2 spike–AXL data and clarifying the unique contribution of the (2-7) fragment among angiotensin peptides.

Common Pitfalls or Misconceptions

• Angiotensin 1/2 (2-7) is not approved for human diagnostic or therapeutic use.
• Its vasoconstrictor effect is well-characterized in vitro, but systemic in vivo data are limited and must not be extrapolated without further study.
• It does not directly inhibit the binding of SARS-CoV-2 to ACE2 or NRP1, but modulates AXL-mediated entry (Oliveira et al., 2025).
• Peptide stability is temperature sensitive; solutions should be kept at -20°C and used short-term only (APExBIO).
• Results from rodent or cell models may not translate directly to human clinical contexts.

Workflow Integration & Parameters

Angiotensin 1/2 (2-7) is utilized in RAS research, cardiovascular modeling, and viral pathogenesis studies. Its chemical stability and solubility make it suitable for diverse assay protocols. For practical guidance on implementation in cell-based models, see this workflow-oriented article, which this article complements by mapping peptide structure to function and updating on viral research applications.

Protocol Parameters

• Reconstitution: Dissolve in sterile water (≥46.6 mg/mL), DMSO (≥78.4 mg/mL), or ethanol (≥2.78 mg/mL) at room temperature for initial stock preparation; mix gently to avoid peptide denaturation.
• Storage: Store lyophilized powder and reconstituted solutions at -20°C. Avoid repeated freeze–thaw cycles for maximum stability (APExBIO).
• Purity assurance: Use only high-purity (≥99.80%) preparations for receptor binding or mechanistic assays to avoid confounding effects from peptide contaminants.
• Recommended concentration for in vitro assays: Empirically determined; start with 1–10 μM based on published RAS peptide benchmarking (Oliveira et al., 2025).
• Short-term use: Prepare working aliquots fresh before each experiment for optimal peptide activity.

Conclusion & Outlook

Angiotensin 1/2 (2-7) is a validated research tool for dissecting the renin-angiotensin signaling pathway. Its unique N-terminal truncation confers distinct properties that facilitate both blood pressure regulation research and the study of viral entry mechanisms. Enhanced spike–AXL binding by this peptide fragment highlights the intersection of cardiovascular and infectious disease research. Further investigation into its structure–function relationships, as well as controlled in vivo studies, are needed to translate bench findings into therapeutic insight. The A1050 kit from APExBIO provides a high-purity, reliable source for continued mechanistic and translational research.